Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 5,782 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bronchial Disease Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of a 10,000 EU Dose of Endotoxin in Allergic and Mildly Asthmatic Adults

NCT00839189
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Seasonal, Asthma
Interventions
Clinical Center Reference Endotoxin (CCRE)
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2006
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 9, 2009 · Synced Oct 29, 2026, 5:14 PM EDT
Completed Not applicable Interventional

Improving Asthma Outcomes in an Urban Pediatric Population

NCT00140439
View directory record Official record
Conditions
Asthma
Interventions
Emergency Department based asthma follow-up clinic
Behavioral
Lead sponsor
Stephen J. Teach, MD, MPH
Other
Eligibility
12 Months to 17 Years
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Oct 29, 2026, 5:14 PM EDT
Recruiting Phase 2 Interventional

SMARCA4/2 Inhibitor for POU2F3-Positive SCLC

NCT07551635
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
FHD-286
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 29, 2026, 5:14 PM EDT
Completed Phase 3 Interventional Results available

A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

NCT04513925
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Atezolizumab, Tiragolumab, Durvalumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
829 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
25
States / cities
Palo Alto, California • Greeley, Colorado • Fort Myers, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 29, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma

NCT03207243
View directory record Official record
Conditions
Asthma
Interventions
GSK3772847, Placebo, Fluticasone propionate/salmeterol, Fluticasone propionate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
33
States / cities
Birmingham, Alabama • Scottsboro, Alabama • Bakersfield, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 29, 2026, 5:14 PM EDT
Completed Phase 1 Interventional

Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer

NCT01784640
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
Hsp90 inhibitor AUY922, pemetrexed disodium, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Oct 29, 2026, 5:14 PM EDT
Recruiting Phase 1Phase 2 Interventional

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

NCT04691817
View directory record Official record
Conditions
Lung Cancer, Nonsmall Cell
Interventions
Atezolizumab, Tocilizumab
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 29, 2026, 5:14 PM EDT
Completed Phase 4 Interventional

Trial of Asthma Patient Education (TAPE)

NCT00148408
View directory record Official record
Conditions
Asthma
Interventions
Montelukast, Education
Drug · Behavioral
Lead sponsor
American Lung Association Asthma Clinical Research Centers
Other
Eligibility
15 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
20
States / cities
Birmingham, Alabama • San Diego, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2010 · Synced Oct 29, 2026, 5:14 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies

NCT03367819
View directory record Official record
Conditions
Prostate Cancer, Non-small Cell Lung Cancer
Interventions
Isatuximab SAR650984, Cemiplimab REGN2810
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Birmingham, Alabama • Atlanta, Georgia • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Oct 29, 2026, 5:14 PM EDT
Completed No phase listed Observational

Motion Correction of Positron Emission Tomography (PET) Data Using Amplitude Gating

NCT00843219
View directory record Official record
Conditions
Lung Cancer
Interventions
PET/CT Scan
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 29, 2026, 5:14 PM EDT
Terminated Phase 2 Interventional

KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer

NCT05027867
View directory record Official record
Conditions
Small-cell Lung Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer Extensive Stage, Small Cell Lung Cancer Recurrent
Interventions
KRT-232
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Fort Myers, Florida • St. Petersburg, Florida • West Palm Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2023 · Synced Oct 29, 2026, 5:14 PM EDT
Terminated Phase 2 Interventional Results available

Radiation Therapy or Observation After Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

NCT00776100
View directory record Official record
Conditions
Lung Cancer
Interventions
clinical observation, radiation therapy
Other · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
168
States / cities
Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 103 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 29, 2026, 5:14 PM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.

NCT02563067
View directory record Official record
Conditions
Asthma
Interventions
QAW039, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
877 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
18
States / cities
Little Rock, Arkansas • San Jose, California • Stockton, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 29, 2026, 5:14 PM EDT
Not listed Phase 2 Interventional

Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00033722
View directory record Official record
Conditions
Lung Cancer
Interventions
folic acid, lometrexol
Dietary Supplement · Drug
Lead sponsor
Tularik
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
7
States / cities
San Francisco, California • Orlando, Florida • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 29, 2026, 5:14 PM EDT
Completed Phase 1 Interventional

MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC

NCT02592577
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Carcinoma
Interventions
Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T
Biological
Lead sponsor
Adaptimmune
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
14
States / cities
Duarte, California • Palo Alto, California • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 29, 2026, 5:14 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer

NCT02779751
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Breast Cancer
Interventions
Abemaciclib, Pembrolizumab, Anastrozole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
7
States / cities
Springdale, Arkansas • San Francisco, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 29, 2026, 5:14 PM EDT
Recruiting Phase 2 Interventional

Rademikibart IV for Acute Asthma and COPD Exacerbation

NCT07705737
View directory record Official record
Conditions
Asthma Acute, COPD Exacerbation Acute
Interventions
Rademikibart
Drug
Lead sponsor
Connect Biopharm LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Miami, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 29, 2026, 5:14 PM EDT
Not listed Phase 1 Interventional

A Study Evaluating MM-310 in Patients With Solid Tumors

NCT03076372
View directory record Official record
Conditions
Solid Tumors, Urothelial Carcinoma, Gastric Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Prostate Adenocarcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Triple Negative Breast Cancer, Endometrial Carcinoma, Soft Tissue Sarcoma
Interventions
MM-310
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Scottsdale, Arizona • San Francisco, California • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Oct 29, 2026, 5:14 PM EDT
Terminated Phase 2 Interventional Results available

Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer

NCT00509366
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Cisplatin & Gemcitabine, Cisplatin & Pemetrexed, Docetaxel & Gemcitabine, Pemetrexed & Gemcitabine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
8
States / cities
Durham, North Carolina • Henderson, North Carolina • Laurinburg, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Oct 29, 2026, 5:14 PM EDT
Completed Not applicable Interventional

Feasibility of a Hepatitis C Virus (HCV) Decision-Making Intervention Among HIV-infected Adults

NCT01472354
View directory record Official record
Conditions
Hepatitis c
Interventions
Leap-c group intervention
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 29, 2026, 5:14 PM EDT
Recruiting Phase 3 Interventional

A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants

NCT07756645
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
ABBV-1480, Pembrolizumab, Carboplatin, Paclitaxel, Nab- Paclitaxel
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
940 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 29, 2026, 5:14 PM EDT
Completed Phase 2 Interventional

Video-Assisted Surgery in Treating Patients With Non-small Cell Lung Cancer

NCT00003692
View directory record Official record
Conditions
Lung Cancer
Interventions
therapeutic thoracoscopy, video-assisted surgery
Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
112
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 72 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 29, 2026, 5:14 PM EDT
Completed Early Phase 1 Interventional

A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease

NCT01274507
View directory record Official record
Conditions
Asthma, Pulmonary Disease, Chronic Obstructive
Interventions
Medical tests
Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
9
States / cities
Birmingham, Alabama • New Haven, Connecticut • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Oct 29, 2026, 5:14 PM EDT
Terminated Phase 1 Interventional

A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer

NCT04432207
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, Squamous Non-small-cell Lung Cancer, Large Cell Carcinoma Lung, Adenocarcinoma Lung
Interventions
IMU-201 (administered as PD1-Vaxx) - Regimen 1, IMU-201 (administered as PD1-Vaxx) - Regimen 2, IMU-201 (administered as PD1-Vaxx) - Regimen 3, Atezolizumab, Standard of care chemotherapy
Biological · Drug
Lead sponsor
Imugene Limited
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Phoenix, Arizona • Hackensack, New Jersey • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 29, 2026, 5:14 PM EDT